1. Scrip
  2. >>Leadership

Narasimhan Promises To Improve Novartis' Image As Top Lawyer Exits

 
• By Sten Stovall

Novartis' top lawyer is taking responsibility for the controversial contract with Essential Consultants and stepping down, amid pledges by the company to polish its tarnished image.

Broom
Novartis' CEO Narasimhan Is Promising To Be An Effective New Broom There • Source: Shutterstock

Novartis AG’s top lawyer Felix Ehrat is taking the fall for the controversial $1.2m in payments he helped arrange to Donald Trump’s attorney, as the Swiss group's newly installed CEO makes fresh promises to clean up the company's ethical act.

Ehrat – who is also an executive board member – announced May 16 that he's stepping down from his post...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Executives On The Move: Four New CEOs Among This Week’s Changes

Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.

Sanofi CFO Says Direct Sales To Patients ‘Certainly Worth Considering’

 
• By Kevin Grogan

François Roger believes fixing inefficiencies is more important than playing with pricing.

Prasad’s Exit From CBER Could Bode Well For Genetic Medicines

 
• By Jessica Merrill

Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

More from Scrip

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death

 
• By Alaric DeArment

The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”